Bardoxolone Blow-Up: Reata/Abbott CKD Drug Halted In Phase III
This article was originally published in The Pink Sheet Daily
Reata has terminated the Phase III BEACON trial for its chronic kidney disease hopeful bardoxolone methyl, partnered with Abbott, due to safety concerns.
You may also be interested in...
Reata Puts Hopes On Partner Study To Support Bardoxolone Resubmission
Reata says partner Kyowa Kirin’s outcomes study of bardoxolone in chronic kidney disease may address the questions cited by the FDA in its complete response letter for Alport syndrome.
Surprise! It’s A Phase III Failure
When Phase III clinical trial failures happen it is a painful blow – to the drug manufacturer, to investors and to patients. Scrip takes a look at some of the biggest Phase III surprises since 2010.
Chronic Kidney Disease Trials Could Gain New Surrogate Endpoints
FDA is considering the use of 30% and 40% reductions in glomerular filtration rate as surrogate endpoints for the development of kidney failure in clinical trials; the current standard is 50%.